Trexquant Investment LP Biotechnology

Trexquant Investment LP

$8.01 Billion
Q1 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
REPL Replimune Group, Inc.	$481M	$1.49 Million 0.02% of portfolio	152,536	Q1 2025 Reduced 21.61%
TBPH Theravance Biopharma, Inc.	$719M	$1.48 Million 0.02% of portfolio	165,424	Q1 2025 Added 9.49%
CDXC Chroma Dex Corp.	$420M	$1.45 Million 0.02% of portfolio	209,786	Q1 2025 Added 671.75%
CLDX Celldex Therapeutics, Inc.	$913M	$1.42 Million 0.02% of portfolio	78,210	Q1 2025 New
XNCR Xencor Inc	$570M	$1.42 Million 0.02% of portfolio	133,360	Q1 2025 Added 60.21%
VCEL Vericel Corp	$2.05B	$1.4 Million 0.02% of portfolio	31,329	Q1 2025 Reduced 64.78%
CRSP Crispr Therapeutics Ag	$3.35B	$1.32 Million 0.02% of portfolio	38,831	Q1 2025 New
ITOS I Teos Therapeutics, Inc.	$362M	$1.13 Million 0.01% of portfolio	188,500	Q1 2025 Added 4.74%
COGT Cogent Biosciences, Inc.	$402M	$1.1 Million 0.01% of portfolio	183,821	Q1 2025 Reduced 33.76%
INVA Innoviva, Inc.	$1.48B	$947,000 0.01% of portfolio	52,283	Q1 2025 New
ALDX Aldeyra Therapeutics, Inc.	$150M	$909,000 0.01% of portfolio	158,117	Q1 2025 Added 38.12%
VNDA Vanda Pharmaceuticals Inc.	$248M	$881,000 0.01% of portfolio	192,110	Q1 2025 Reduced 15.25%
RLAY Relay Therapeutics, Inc.	$420M	$850,000 0.01% of portfolio	324,469	Q1 2025 Reduced 66.83%
CRMD Cor Medix Inc.	$568M	$834,000 0.01% of portfolio	135,487	Q1 2025 Added 588.87%
IDYA Ideaya Biosciences, Inc.	$1.01B	$816,000 0.01% of portfolio	49,824	Q1 2025 Reduced 53.5%
IMTX Immatics N.V.	$441M	$782,000 0.01% of portfolio	173,518	Q1 2025 New
ETNB 89bio, Inc.	$473M	$721,000 0.01% of portfolio	99,183	Q1 2025 New
AVXL Anavex Life Sciences Corp.	$606M	$610,000 0.01% of portfolio	71,107	Q1 2025 Reduced 0.51%
ADMA Adma Biologics, Inc.	$3.92B	$573,000 0.01% of portfolio	28,907	Q1 2025 Reduced 16.05%
STOK Stoke Therapeutics, Inc.	$429M	$572,000 0.01% of portfolio	86,140	Q1 2025 Reduced 16.39%
ABEO Abeona Therapeutics Inc.	$37.3M	$567,000 0.01% of portfolio	119,274	Q1 2025 Added 74.08%
CGEM Cullinan Oncology, Inc.	$399M	$518,000 0.01% of portfolio	68,467	Q1 2025 New
ORIC Oric Pharmaceuticals, Inc.	$388M	$424,000 0.01% of portfolio	76,093	Q1 2025 New
TERN Terns Pharmaceuticals, Inc.	$134M	$385,000 0.0% of portfolio	139,609	Q1 2025 Reduced 44.87%
MGTX Meira G Tx Holdings PLC	$256M	$300,000 0.0% of portfolio	44,318	Q1 2025 Added 12.63%
CELC Celcuity Inc.	$196M	$272,000 0.0% of portfolio	26,920	Q1 2025 Added 131.27%
RCKT Rocket Pharmaceuticals, Inc.	$210M	$250,000 0.0% of portfolio	37,613	Q1 2025 New
URGN Uro Gen Pharma Ltd.	$131M	$170,000 0.0% of portfolio	15,454	Q1 2025 Reduced 91.04%
FHTX Foghorn Therapeutics Inc.	$172M	$129,000 0.0% of portfolio	35,585	Q1 2025 Reduced 42.23%
GLUE Monte Rosa Therapeutics, Inc.	$216M	$121,000 0.0% of portfolio	26,188	Q1 2025 New
TRDA Entrada Therapeutics, Inc.	$259M	$100,000 0.0% of portfolio	11,143	Q1 2025 New
OMER Omeros Corp	$223M	$88,000 0.0% of portfolio	10,760	Q1 2025 New
SBTX Silverback Therapeutics, Inc.	$0	$0 0.0% of portfolio	100,769	Q1 2025 Added 78.15%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.